Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Iasibon
Iasibon 50 mg film coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-124067 · Präparat HOS-095779
Medicinal product -Food Interactions
Products containing calcium and other multivalent cations (such as aluminium, magnesium, iron),
including milk and food, are likely to interfere with absorption of Iasibon tablets. Therefore, with such
products, including food, intake must be delayed at least 30 minutes following oral administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T17:38:00Z · SHA-256 858d65121d0c57fc23c7219d9cfeb81383762c7e90e23c1b5a81b14cfe281605 · Passage 14ea7cb6f046fa59ae8ad88b3e7eb40b151d2e1df43561ad499f20351149a87a · Zeichen 0–338 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-213955 · Präparat HOS-155234
8
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
NARCOTIC ANALGESICS
Methadone* R(-) methadone AUC ↓ 16% No dose adjustments are required
60-100 mg once daily, R(-) methadone Cmin ↓ 22% when initiating co-administration of
individualised dose R(-) methadone Cmax ↓ 14% methadone with rilpivirine. However,
rilpivirine AUC ↔* clinical monitoring is recommended as
rilpivirine Cmin ↔* methadone maintenance therapy may
rilpivirine Cmax ↔* need to be adjusted in some patients.
* based on historic controls
ANTIARRHYTHMICS
Digoxin* digoxin AUC ↔ No dose adjustment is required.
digoxin Cmin NA
digoxin Cmax ↔
ANTICOAGULANTS
Dabigatran etexilate Not studied. A risk for increases in The combination of rilpivirine and
dabigatran plasma concentrations dabigatran etexilate should be used
cannot be excluded. with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) digoxin (HOS-086172) dabigatran (HOS-112096) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage a82647616d2369ed93f5c1c0ca58dde62668e3f570c10a0d9aee6e832fcc541a · Zeichen 14265–16215 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-214008 · Präparat HOS-155234
(reduced absorption due to gastric
pH increase)
Lansoprazole Not studied. Significant decreases
Rabeprazole in rilpivirine plasma concentrations
Pantoprazole are expected.
Esomeprazole
(reduced absorption due to gastric
pH increase)
H2-RECEPTOR ANTAGONISTS
Famotidine*# rilpivirine AUC ↓ 9% The combination of rilpivirine and
40 mg single dose taken rilpivirine Cmin NA H2-receptor antagonists should be used
12 hours before rilpivirine Cmax ↔ with particular caution. Only
rilpivirine H2-receptor antagonists that can be
Famotidine*# rilpivirine AUC ↓ 76% dosed once daily should be used.
40 mg single dose taken rilpivirine Cmin NA A strict dosing schedule, with intake of
2 hours before rilpivirine rilpivirine Cmax ↓ 85% H2-receptor antagonists at least
12 hours before or at least 4 hours
(reduced absorption due to gastric after rilpivirine should be used.
pH increase)
Famotidine*# rilpivirine AUC ↑ 13%
40 mg single dose taken rilpivirine Cmin NA
4 hours after rilpivirine rilpivirine Cmax ↑ 21%
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 127a046a3ba0f0f2919bad57eab9493f739a4627df3219ad6f8640932758cd01 · Zeichen 11316–13658 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-215296 · Präparat HOS-155418
14
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
(dose) Cmax, Cmin with confidence efavirenz
intervals if availablea
(mechanism)
increased hepatic metabolism by an increased dose of praziquantel
efavirenz. could be considered.
ACID-REDUCING AGENTS
Aluminium hydroxide- Neither aluminium/magnesium Co-administration of efavirenz
magnesium hydroxide- hydroxide antacids nor famotidine with medicinal products that alter
simethicone antacid/efavirenz altered the absorption of efavirenz. gastric pH would not be expected
(30 ml single dose/400 mg single to affect efavirenz absorption.
dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): praziquantel (HOS-132858) famotidine (HOS-112087) magnesium (HOS-085165) simethicone (HOS-118210)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage 43cc6130d235a7967a885c134a8539fc0b28497563a2c9d1c834b3ceacca5698 · Zeichen 38868–39933 im Abschnitt
Wechselwirkungen · Capecitabine Teva
Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-215405 · Präparat HOS-155434
Antacid
The effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the
pharmacokinetics of capecitabine was investigated. There was a small increase in plasma
concentrations of capecitabine and one metabolite (5’-DFCR); there was no effect on the 3 major
metabolites (5’-DFUR, 5-FU and FBAL).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T15:40:00Z · SHA-256 360b33238effee7033c9ecfa3731a36e172b67d4837e971f09a6e80d5cda73df · Passage f4c059b31160fd01af59e5c5c3ff4c45d72b1eb6df9d3cff970ffd9003f1a10a · Zeichen 3188–3504 im Abschnitt
Wechselwirkungen · Capecitabine Accord
Capecitabine Accord 150 mg film-coated tablets Capecitabine Accord 300 mg film-coated tablets Capecitabine Accord 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-125508 · Präparat HOS-096081
Antacid
The effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the
pharmacokinetics of capecitabine was investigated. There was a small increase in plasma
concentrations of capecitabine and one metabolite (5’-DFCR); there was no effect on the 3 major
metabolites (5’-DFUR, 5-FU and FBAL).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T15:07:00Z · SHA-256 31136a37a67bcc7d3d37a3db0a926c5402c9346bcaefe911a69ae0fa32bf9225 · Passage f4c059b31160fd01af59e5c5c3ff4c45d72b1eb6df9d3cff970ffd9003f1a10a · Zeichen 3189–3505 im Abschnitt
Wechselwirkungen · Capecitabine Medac
Capecitabine medac 150 mg film-coated tablets Capecitabine medac 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-218205 · Präparat HOS-216183
Antacid
The effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the
pharmacokinetics of capecitabine was investigated. There was a small increase in plasma
concentrations of capecitabine and one metabolite 5’-deoxy-5-fluorocytidine (5’-DFCR); there was no
effect on the 3 major metabolites: 5’-deoxy-5-fluorouridine (5’-DFUR), 5-FU and α-fluoro-β-alanine
(FBAL).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): magnesium (HOS-085165) alanine (HOS-088949)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T02:00:00Z · SHA-256 911762332dd30fd042dfa8a081c0eb1ec9e9d586a7284c79027e9cf3a76f4cf9 · Passage efa975a739193e75046235ac6d336b42465975629b328f872009860d7e0d2110 · Zeichen 3199–3588 im Abschnitt
Wechselwirkungen · Stribild
Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-218471 · Präparat HOS-216207
For coadministration of
cutaneously-administered
corticosteroids sensitive to CYP3A
inhibition, refer to the prescribing
information of the corticosteroid for
conditions or uses that augment its
systemic absorption.
MEDICINAL PRODUCTS or ORAL SUPPLEMENTS CONTAINING POLYVALENT CATIONS (e.g. Mg, Al,
Ca, Fe, Zn)
Magnesium/aluminium-containing Elvitegravir (antacid suspension after ± It is recommended to separate
antacid suspension (20 mL single 2 hours): Stribild and administration of
dose)/Elvitegravir (50 mg single AUC: ↔ antacids, medicinal products or oral
dose)/Ritonavir (100 mg single Cmin: ↔ supplements containing polyvalent
dose) Cmax: ↔ cations by at least 4 hours.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-23T16:51:00Z · SHA-256 d3f228ded6370d77784fda3a53beaff9f1155c63df0f682c7673ee3cdc2ccdc5 · Passage a1bcd3e7b108929b3dfffc499c250903f839dfba28f0cd9d07875369e8c46307 · Zeichen 25714–26999 im Abschnitt
Wechselwirkungen · Ecansya (previously Capecitabine Krka)
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-218778 · Präparat HOS-216253
Antacid: the effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the
pharmacokinetics of capecitabine was investigated. There was a small increase in plasma
concentrations of capecitabine and one metabolite (5’-DFCR); there was no effect on the 3 major
metabolites (5’-DFUR, 5-FU and FBAL).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T13:15:00Z · SHA-256 8ecca9f77f74b0d59963476fed069ac10026c03322dd05aa8a80f379bea1ba08 · Passage a36ad79abc4d35debc1dedadaf1a92774fafe10c416c7481e56e2ac1e83abb4b · Zeichen 3139–3456 im Abschnitt
Wechselwirkungen · Feraccru
Feraccru 30 mg hard capsules · Abschnitt 4.5 · PDF-Seite 3
HOS-128830 · Präparat HOS-096637
Absorption of oral iron may be reduced by calcium and magnesium salts (such as magnesium
trisilicate). Administration of iron preparations with such compounds should be separated by at least 2
hours.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T15:59:00Z · SHA-256 b2d699d0ce35a74de8558e02a2453b5b268ff8751bf546e8905e41445f10e069 · Passage 3f391677667b3d813a7944b8e8a724608ce7faea3bc1974062bc5b534d8dd8a1 · Zeichen 597–796 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-129166 · Präparat HOS-096689
9
Magnesium/ Dolutegravir Magnesium/ aluminium-containing antacid should
aluminium-containing AUC 74% be taken well separated in time from the
antacid Cmax 72% administration of dolutegravir (minimum 2 hours
(Complex binding to after or 6 hours before).
polyvalent ions)
Calcium supplements Dolutegravir - When taken with food, Tivicay and supplements
(fasted intake) AUC 39% or multivitamins containing calcium, iron or
Cmax 37% magnesium can be taken at the same time.
C24 39% - If Tivicay is taken in a fasted state, such
(Complex binding to supplements should be taken a minimum 2 hours
polyvalent ions) after or 6 hours before the intake of Tivicay.
Iron supplements Dolutegravir
(fasted intake) AUC 54% The stated reductions in dolutegravir exposure
Cmax 57% were observed with the intake of dolutegravir and
C24 56% these supplements during fasted conditions. In fed
(Complex binding to state, the changes in exposure following intake
polyvalent ions) together with calcium or iron supplements were
Multivitamin Dolutegravir modified by the food effect, resulting in an
(containing calcium, AUC 33% exposure similar to that obtained with dolutegravir
iron and magnesium) Cmax 35% administered in the fasted state.
(fasted intake) C24 32%
(Complex binding to
polyvalent ions)
Corticosteroids
Prednisone Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin Metformin A dose adjustment of metformin should be
When co-administered with considered when starting and stopping
dolutegravir 50mg once coadministration of dolutegravir with metformin,
daily: to maintain glycaemic control. In patients with
Metformin moderate renal impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with dolutegravir, because of the
When co-administered with increased risk for lactic acidosis in patients with
dolutegravir 50mg twice moderate renal impairment due to increased
daily: metformin concentration (section 4.4).
Metformin
AUC 145 %
Cmax 111%
Antimycobacterials
Rifampicin Dolutegravir The recommended adult dose of dolutegravir is
AUC 54% 50 mg twice daily when co-administered with
Cmax 43% rifampicin in the absence of integrase class
Cτ 72% resistance. In paediatric patients the weight-based
(induction of UGT1A1 and once daily dose should be administered twice
CYP3A enzymes) daily.
In the presence of integrase class resistance this
combination should be avoided (see section 4.4).
Rifabutin Dolutegravir No dose adjustment is necessary.
AUC 5%
Cmax 16%
Cτ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage f7cdc948f0f37aad9317a603dc4efadabd031fe5fda7aad9c55b87b5ea9476f5 · Zeichen 13303–17453 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 38–39
HOS-129200 · Präparat HOS-096689
38
Lopinavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 4%
Cmax 0%
C24 6%
Other Antiviral agents
Daclatasvir Dolutegravir Daclatasvir did not change dolutegravir plasma
AUC 33% concentration to a clinically relevant extent.
Cmax 29% Dolutegravir did not change daclatasvir plasma
C 45% concentration. No dose adjustment is necessary.
Daclatasvir
Other agents
Potassium channel blocker
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine) plasma concentration via inhibition of OCT2
transporter; co-administration has not been studied.
Fampridine co-administration with dolutegravir is
contraindicated.
Anticonvulsants
Carbamazepine Dolutegravir The recommended adult dose of dolutegravir
AUC 49% should be given twice daily when co-administered
Cmax 33% with carbamazepine. In paediatric patients the
C 73% weight-based once daily dose should be
administered twice daily. Alternatives to
carbamazepine should be used where possible for
INI resistant patients.
Oxcarbazepine Dolutegravir The recommended adult dose of dolutegravir
Phenytoin (Not studied, decrease should be given twice daily when co-administered
Phenobarbital expected due to induction of with these metabolic inducers. In paediatric
UGT1A1 and CYP3A patients the weight-based once daily dose should
enzymes, a similar reduction be administered twice daily. Alternative
in exposure as observed combinations that do not include these metabolic
with carbamazepine is inducers should be used where possible in INI-
expected) resistant patients.
Azole anti-fungal agents
Ketoconazole Dolutegravir No dose adjustment is necessary. Based on data
Fluconazole (Not studied) from other CYP3A4 inhibitors, a marked increase
Itraconazole is not expected.
Posaconazole
Voriconazole
Herbal products
St. John’s wort Dolutegravir The recommended adult dose of dolutegravir
(Not studied, decrease should be given twice daily when co-administered
expected due to induction of with St. John’s wort. In paediatric patients the
UGT1A1 and CYP3A weight-based once daily dose should be
enzymes, a similar reduction administered twice daily. Alternative combinations
in exposure as observed that do not include St. John’s wort should be used
with carbamazepine is where possible in INI-resistant patients.
expected)
Antacids and supplements
Magnesium/ Dolutegravir Magnesium/ aluminium-containing antacid should
aluminium-containing AUC 74% be taken well separated in time from the
antacid Cmax 72% administration of dolutegravir (minimum 2 hours
(Complex binding to after or 6 hours before).
polyvalent ions)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) daclatasvir (HOS-119742) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) potassium (HOS-086929) magnesium (HOS-085165) phenytoin (HOS-084531) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage b1f6422443cc14d5f9a656df820bb5371607b232b50be9270e4f54627fc6d01d · Zeichen 9496–13843 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 39–40
HOS-129201 · Präparat HOS-096689
39
Calcium supplements Dolutegravir - When taken with food, Tivicay and supplements
(fasted intake) AUC 39% or multivitamins containing calcium, iron or
Cmax 37% magnesium can be taken at the same time.
C24 39% - If Tivicay is taken in a fasted state, such
(Complex binding to supplements should be taken a minimum 2 hours
polyvalent ions) after or 6 hours before the intake of Tivicay.
Iron supplements Dolutegravir
(fasted intake) AUC 54% The stated reductions in dolutegravir exposure
Cmax 57% were observed with the intake of dolutegravir and
C24 56% these supplements during fasted conditions. In fed
(Complex binding to state, the changes in exposure following intake
polyvalent ions) together with calcium or iron supplements were
Multivitamin Dolutegravir modified by the food effect, resulting in an
(containing calcium, AUC 33% exposure similar to that obtained with dolutegravir
iron and magnesium) Cmax 35% administered in the fasted state.
(fasted intake) C24 32%
(Complex binding to
polyvalent ions)
Corticosteroids
Prednisone Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin Metformin A dose adjustment of metformin should be
When co-administered with considered when starting and stopping
dolutegravir 50mg film- coadministration of dolutegravir with metformin,
coated tablets once daily: to maintain glycaemic control. In patients with
Metformin moderate renal impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with dolutegravir, because of the
When co-administered with increased risk for lactic acidosis in patients with
dolutegravir 50mg film- moderate renal impairment due to increased
coated tablets twice daily: metformin concentration (section 4.4).
Metformin
AUC 145 %
Cmax 111%
Antimycobacterials
Rifampicin Dolutegravir The recommended adult dose of dolutegravir
AUC 54% should be given twice daily when co-administered
Cmax 43% with rifampicin in the absence of integrase class
Cτ 72% resistance. In paediatric patients the weight-based
(induction of UGT1A1 and once daily dose should be administered twice
CYP3A enzymes) daily.
In the presence of integrase class resistance this
combination should be avoided (see section 4.4).
Rifabutin Dolutegravir No dose adjustment is necessary.
AUC 5%
Cmax 16%
Cτ 30%
(induction of UGT1A1 and
CYP3A enzymes)
Oral contraceptives
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage cf7ded37100a7c771efb0096a21a323a6de8cfc601cd1795a94f75791a79825c · Zeichen 13895–17824 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-129278 · Präparat HOS-096703
13
Magnesium/ Dolutegravir ↓ Magnesium/ aluminium-containing
aluminium-containing AUC ↓ 74% antacids should be taken well separated
antacids/Dolutegravir Cmax ↓ 72% in time from the administration of
Triumeq (minimum 2 hours after or 6
(Complex binding to hours before the intake of Triumeq).
polyvalent ions)
Calcium Dolutegravir ↓ - When taken with food, Triumeq and
supplements/Dolutegravir AUC ↓ 39% supplements or multivitamins containing
Cmax ↓ 37% calcium, iron or magnesium can be taken
C24 ↓ 39% at the same time.
(Complex binding to - If Triumeq is taken in a fasted state,
polyvalent ions) such supplements should be taken a
Iron supplements/Dolutegravir Dolutegravir ↓ minimum 2 hours after or 6 hours before
AUC ↓ 54% the intake of Triumeq.
Cmax ↓ 57%
C24 ↓ 56% The stated reductions in dolutegravir
(Complex binding to exposure were observed with the intake
polyvalent ions) of dolutegravir and these supplements
Multivitamins (containing Dolutegravir ↓ during fasted conditions. In fed state, the
calcium, iron and magnesium) AUC ↓ 33% changes in exposure following intake
/Dolutegravir Cmax ↓ 35% together with calcium or iron
C24 ↓ 32% supplements were modified by the food
effect, resulting in an exposure similar to
that obtained with dolutegravir
administered in the fasted state.
Corticosteroids
Prednisone Dolutegravir ↔ No dose adjustment is necessary.
AUC ↑ 11%
Cmax ↑ 6%
Cτ ↑ 17%
Antidiabetics
Metformin/Dolutegravir Metformin ↑ A dose adjustment of metformin should
Dolutegravir ↔ be considered when starting and
When co-administered stopping coadministration of
with dolutegravir 50mg dolutegravir with metformin, to maintain
QD: glycaemic control. In patients with
Metformin moderate renal impairment a dose
AUC ↑ 79% adjustment of metformin should be
Cmax ↑ 66% considered when coadministered with
When co-administered dolutegravir, because of the increased
with dolutegravir 50mg risk for lactic acidosis in patients with
BID: moderate renal impairment due to
Metformin increased metformin concentration
AUC ↑ 145 % (section 4.4).
Cmax ↑ 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
(Not studied, decrease is 50 mg twice daily when co-
expected due to induction administered with St. John’s wort. As
of UGT1A1 and CYP3A Triumeq is a fixed dose tablet, an
enzymes, a similar additional 50 mg tablet of dolutegravir
reduction in exposure as should be administered, approximately
observed with 12 hours after Triumeq for the duration
carbamazepine is of the St John’s wort co-administration
expected) (a separate preparation of dolutegravir is
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage c8fee2375199538a75c25c7b72890728decb53cdd903d7de9ec1464e917c5665 · Zeichen 24627–29346 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50
HOS-129363 · Präparat HOS-096703
Sorbitol
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine When possible, avoid chronic
13.4 g)/Lamivudine oral solution 300 mg coadministration of Triumeq with
medicinal products containing sorbitol
Lamivudine:
or other osmotic acting poly-alcohols or
AUC ↓ 14%; 32%; 36% monosaccharide alcohols (eg: xylitol,
mannitol, lactitol, maltitol). Consider
Cmax ↓ 28%; 52%, 55%.
more frequent monitoring of HIV-1 viral
load when chronic coadministration
cannot be avoided.
Potassium channel blockers
Fampridine (also known as Fampridine ↑ Co-administration of dolutegravir has
dalfampridine)/Dolutegravir the potential to cause seizures due to
increased fampridine plasma
concentration via inhibition of OCT2
transporter; co-administration has not
been studied. Fampridine co-
administration with Triumeq is
contraindicated (see section 4.3).
Antacids and supplements
Magnesium/ Dolutegravir ↓ Magnesium/ aluminium-containing
aluminium-containing AUC ↓ 74% antacids should be taken well separated
antacids/Dolutegravir Cmax ↓ 72% in time from the administration of
Triumeq (minimum 2 hours after or 6
(Complex binding to hours before the intake of Triumeq).
polyvalent ions)
Calcium Dolutegravir ↓ - When taken with food, Triumeq and
supplements/Dolutegravir AUC ↓ 39% supplements or multivitamins containing
Cmax ↓ 37% calcium, iron or magnesium can be taken
C24 ↓ 39% at the same time.
(Complex binding to - If Triumeq is taken in a fasted state,
polyvalent ions) such supplements should be taken a
Iron supplements/Dolutegravir Dolutegravir ↓ minimum 2 hours after or 6 hours before
AUC ↓ 54% the intake of Triumeq.
Cmax ↓ 57%
C24 ↓ 56%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) calcium (HOS-085615) iron (HOS-085656) xylitol (HOS-085846) dalfampridine (HOS-124191) mannitol (HOS-085847) lactitol (HOS-085848) potassium (HOS-086929) magnesium (HOS-085165) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage e1b3a9b322dc8105f415a52dcb6e350ae5cd5eb4c2cfe44e909aca42e727f58f · Zeichen 19030–22339 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50–52
HOS-129364 · Präparat HOS-096703
50
(Complex binding to The stated reductions in dolutegravir
polyvalent ions) exposure were observed with the intake
Multivitamins (containing Dolutegravir ↓ of dolutegravir and these supplements
calcium, iron and magnesium) AUC ↓ 33% during fasted conditions. In fed state, the
/Dolutegravir Cmax ↓ 35% changes in exposure following intake
C24 ↓ 32% together with calcium or iron
supplements were modified by the food
effect, resulting in an exposure similar to
that obtained with dolutegravir
administered in the fasted state.
Corticosteroids
Prednisone Dolutegravir ↔ No dose adjustment is necessary.
AUC ↑ 11%
Cmax ↑ 6%
Cτ ↑ 17%
Antidiabetics
Metformin/Dolutegravir Metformin ↑ A dose adjustment of metformin should
Dolutegravir ↔ be considered when starting and
When co-administered stopping coadministration of
with dolutegravir 50mg dolutegravir with metformin, to maintain
QD: glycaemic control. In patients with
Metformin moderate renal impairment a dose
AUC ↑ 79% adjustment of metformin should be
Cmax ↑ 66% considered when coadministered with
When co-administered dolutegravir, because of the increased
with dolutegravir 50mg risk for lactic acidosis in patients with
BID: moderate renal impairment due to
Metformin increased metformin concentration
AUC ↑ 145 % (section 4.4).
Cmax ↑ 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
(Not studied, decrease should be adjusted when co-
expected due to induction administered with St. John’s wort.
of UGT1A1 and CYP3A
enzymes, a similar Dosing recommendations are provided
reduction in exposure as in Table 2 (see section 4.2)
observed with
carbamazepine is
expected)
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no Pharmacodynamic
Norgestromin EE ↔ effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC ↑ 3% Follicle Stimulating Hormone (FSH) and
Cmax ↓ 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Triumeq.
NGMN ↔
AUC ↓ 2%
Cmax ↓ 11%
Antihypertensive
Riociguat/Abacavir Riociguat ↑ Riociguat dose may need to be reduced,
consult the riociguat prescribing
In vitro, abacavir inhibits
information for dosing
CYP1A1. Concomitant
recommendations.
administration of a single
51
dose of riociguat (0.5 mg)
to HIV patients receiving
Triumeq led to an
approximately three-fold
higher riociguat AUC(0-∞)
when compared to
historical riociguat
AUC(0-∞) reported in
healthy subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) riociguat (HOS-086293) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 4f0d85e516680fd44841c8a2084bad237df81c83647e075fbfa5f388b51c50c4 · Zeichen 22392–27416 im Abschnitt
Wechselwirkungen · Rezolsta
REZOLSTA 800 mg/150 mg film-coated tablets REZOLSTA 675 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-220464 · Präparat HOS-216626
10
CCR5 ANTAGONIST
Maraviroc Based on theoretical The recommended dose of
150 mg twice daily considerations REZOLSTA is maraviroc is 150 mg twice daily
expected to increase maraviroc when co-administered with
plasma concentrations. REZOLSTA. For further details,
(CYP3A inhibition) consult the maraviroc Summary
of Product Characteristics.
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical Co-administration of
considerations REZOLSTA is REZOLSTA with alfuzosin is
expected to increase alfuzosin contraindicated (see section 4.3).
plasma concentrations.
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Based on theoretical The concomitant use with
considerations REZOLSTA is REZOLSTA may require to
expected to increase alfentanil lower the dose of alfentanil and
plasma concentrations. requires monitoring for risks of
prolonged or delayed respiratory
depression.
ANTACIDS
Aluminium/magnesium No mechanistic interaction REZOLSTA and antacids can be
hydroxide expected based on theoretical used concomitantly without dose
Calcium carbonate consideration. adjustment.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Based on theoretical Caution is warranted and
Flecainide considerations REZOLSTA is therapeutic concentration
Lidocaine (systemic) expected to increase these monitoring, if available, is
Mexiletine antiarrhythmic plasma recommended for these
Propafenone concentrations. antiarrhythmics when
(CYP3A and/or CYP2D6 co-administered with
inhibition) REZOLSTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) maraviroc (HOS-086186) magnesium (HOS-085165) calcium carbonate (HOS-088370)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T17:33:00Z · SHA-256 fd4a09675891eba65ab2ce0a1cb84ffd3afbb1ff64ec7131830fe2eae67d87dc · Passage b97229da33eb67bb20f3fe46097bdf1c60123e3bf0314715dda5abfcb6aa53ca · Zeichen 12037–14486 im Abschnitt
Wechselwirkungen · Rezolsta
REZOLSTA 600 mg/90 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 44–45
HOS-220555 · Präparat HOS-216626
44
HIV Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz Based on theoretical Co-administration of
considerations efavirenz is REZOLSTA and efavirenz is not
expected to decrease darunavir recommended.
and/or cobicistat plasma
concentrations. This recommendation is different
(CYP3A induction) from ritonavir-boosted darunavir.
Consult the Summary of Product
Characteristics for darunavir for
further details.
Etravirine Based on theoretical Co-administration of
considerations etravirine is REZOLSTA and etravirine is not
expected to decrease darunavir recommended.
and/or cobicistat plasma
concentrations. This recommendation is different
(CYP3A induction) from ritonavir-boosted darunavir.
Consult the Summary of Product
Characteristics for darunavir for
further details.
Nevirapine Based on theoretical Co-administration of
considerations nevirapine is REZOLSTA and nevirapine is
expected to decrease darunavir not recommended.
and/or cobicistat plasma
concentrations, (CYP3A This recommendation is different
induction). REZOLSTA is from ritonavir-boosted darunavir.
expected to increase nevirapine Consult the Summary of Product
plasma concentrations. Characteristics for darunavir for
(CYP3A inhibition) further details.
Rilpivirine Based on theoretical Co-administration of
considerations REZOLSTA is REZOLSTA and rilpivirine can
expected to increase rilpivirine be used without dose
plasma concentrations. adjustments, as the expected
(CYP3A inhibition) increase in rilpivirine
concentrations is not considered
clinically relevant.
CCR5 ANTAGONIST
Maraviroc Based on theoretical The recommended dose of
150 mg twice daily considerations REZOLSTA is maraviroc is 150 mg twice daily
expected to increase maraviroc when co-administered with
plasma concentrations. REZOLSTA. For further details,
(CYP3A inhibition) consult the maraviroc Summary
of Product Characteristics.
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical Co-administration of
considerations REZOLSTA is REZOLSTA with alfuzosin is
expected to increase alfuzosin contraindicated (see section 4.3).
plasma concentrations.
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Based on theoretical The concomitant use with
considerations REZOLSTA is REZOLSTA may require to
expected to increase alfentanil lower the dose of alfentanil and
plasma concentrations. requires monitoring for risks of
prolonged or delayed respiratory
depression.
ANTACIDS
Aluminium/magnesium No mechanistic interaction REZOLSTA and antacids can be
hydroxide expected based on theoretical used concomitantly without dose
Calcium carbonate consideration. adjustment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) etravirine (HOS-088088) maraviroc (HOS-086186) rilpivirine (HOS-088090) efavirenz (HOS-087947) nevirapine (HOS-088064) magnesium (HOS-085165) calcium carbonate (HOS-088370)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T17:33:00Z · SHA-256 fd4a09675891eba65ab2ce0a1cb84ffd3afbb1ff64ec7131830fe2eae67d87dc · Passage 6e1b3e4b1796078e18749b9e9af3a9e0a730d0c8cdee829737f2e0f1407993e2 · Zeichen 8629–13819 im Abschnitt
Wechselwirkungen · Ebilfumin
Ebilfumin 30 mg hard capsules Ebilfumin 45 mg hard capsules Ebilfumin 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7–8
HOS-220750 · Präparat HOS-216680
7
Additional information
No pharmacokinetic interactions between oseltamivir or its major metabolite have been observed
when co-administering oseltamivir with paracetamol, acetylsalicylic acid, cimetidine, antacids
(magnesium and aluminium hydroxides and calcium carbonates), rimantadine or warfarin (in subjects
stable on warfarin and without influenza).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) calcium (HOS-085615) magnesium (HOS-085165) warfarin (HOS-085950) rimantadine (HOS-110033)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-02T13:36:00Z · SHA-256 a02287a219a00b5644f9da100af779b3b4dbf902e2703750897d41f1aa30ad3a · Passage 6ddad12fddaa1672801b27648480a9034e0473a955700df8bed324a9161200fc · Zeichen 1325–1681 im Abschnitt
Wechselwirkungen · Cuprior
Cuprior 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-222509 · Präparat HOS-217032
Although there is no evidence that calcium or magnesium antacids alter the efficacy of trientine, it is
good practice to separate their administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-23T12:36:00Z · SHA-256 2b9d988407727204ac2dce57e57a71f718206c1b0a2b113ba0afcaefe23af5d6 · Passage a2286521954828f13a120f6ca1b77c304e65d2ea824d4ace1a70f881ff39544f · Zeichen 992–1143 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.